Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
signs and symptoms pathological conditions | D013568 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
SANCUSO | Cumberland Pharmaceuticals | N-022198 RX | 2008-09-12 | 1 products, RLD, RS |
SUSTOL | Heron Therapeutics | N-022445 RX | 2016-08-09 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
granisetron | ANDA | 2022-11-15 |
granisetron hydrochloride | ANDA | 2024-02-29 |
sancuso | New Drug Application | 2024-11-04 |
sustol | New Drug Application | 2024-09-30 |
Code | Description |
---|---|
J1626 | Injection, granisetron hydrochloride, 100 mcg |
J1627 | Injection, granisetron, extended-release, 0.1 mg |
Q0166 | Granisetron hydrochloride, 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen |
S0091 | Granisetron hydrochloride, 1 mg (for circumstances falling under the medicare statute, use q0166) |
Drug common name | Granisetron |
INN | granisetron |
Description | 1-Methyl-N-{9-methyl-9-azabicyclo[3.3.1]nonan-3-yl}-1H-indazole-3-carboxamide is a member of indazoles and an aromatic amide. |
Classification | Small molecule |
Drug class | serotonin 5-HT3 receptor antagonists |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2 |
PDB | — |
CAS-ID | 107007-99-8 |
RxCUI | — |
ChEMBL ID | CHEMBL289469 |
ChEBI ID | — |
PubChem CID | 3510 |
DrugBank | DB00889 |
UNII ID | WZG3J2MCOL (ChemIDplus, GSRS) |